The progression of isocitrate dehydrogenase (IDH) mutations from laboratory findings to clinically validated therapeutic opportunities represents precision oncology's most compelling success stories. The modern Isocitrate Dehydrogenase Inhibitors Market stands as a strategically important oncology therapeutic area, driven by sophisticated biological understanding, pivotal regulatory...